ACTHIV® 2024 FACULTY EDUCATOR AND

PLANNING COMMITTEE DISCLOSURES

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the FDA. Academy and ACTHIV® do not recommend the use of any agent outside of the labeled indications. Faculty will disclose such discussion at the time of their sessions.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, or ACTHIV®. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.

FACULTY EDUCATOR DISCLOSURES

The following individuals have no relevant financial

relationships with ineligible companies to disclose:

  • Tracy Agee, BA, BSN, MSN
  • Melissa Badowski, PharmD, MPH
  • Cedric Bien-Gund, MD
  • Bradley Buchheit, MD, MS
  • Jonathan Colasanti, MD, MSPH
  • Francine Cournos, MD
  • Monica Gandhi, MD, MPH
  • Mark Holtan PharmD, BCACP, AAHIVP
  • Jeff W. Huyett, MS
  • Toby Maurer, MD
  • Blake Max, PharmD
  • Lorenzo McFarland, DHA, MPH, MSW
  • Sudipa Sarkar, MD
  • Anandi Sheth, MD, MSc
  • Eugenia Siegler, MD
  • Karen Slazinski, PharmD
  • Bradley Smith, PharmD, BCACP, AAHIVP
  • Sancta St. Cyr, MD, MPH
  • Mehul Tejani, MD, MPH
  • Jessie Torgersen, MD, MHS, MSCE
  • Virginia Triant, MD, MPH

The following individuals have relevant financial

relationships with ineligible companies to disclose

  • Meena Bansal, MD: Advisory Board/Consultant - The Kinetix Group, Madrigal, Pfizer, Theratechnologies, Fibronostics, Novo Nordisk, GlaxoSmithKline, Merck, Boston Pharma, Intercept*, Myovant*; Grant/Research Support - Pfizer, The Kinetix Group, Histoindex 
  • Sara Bares, MD, FIDSA: Advisory Board/Consultant - Gilead Sciences; Grant Recipient/Research Support - GlaxoSmithKline/ViiV Healthcare, Janssen 
  • Eric Daar, MD: Advisory Board/Consultant - Gilead Sciences, ViiV Healthcare, Theratechnologies; Grant Receiptent/Research Support - Gilead Sciences, ViiV Healthcare 
  • Kristine Erlandson, MD, MS: Advisory Board/Consultant (funds paid to employer) - Gilead Sciences, Merck, ViiV Healthcare; Grant Recipient/Research Support (through institution) - Gilead Sciences 
  • Derek Fine, MD: Advisory Board/Consultant - Macrogenics (Drug safety monitoring board); Expert Witness: Gilead Sciences 
  • Vincent Guilamo-Ramos, PhD, MPH, LCSW, RN, ANP-BC, PMHNP-BC, FAAN: Advisory Board/ Consultant - ViiV Healthcare; Grant Recipient/Research Support - ViiV Healthcare 
  • Peter Hunt, MD: Advisory Board/Consultant - Biotron, Merck*, ViiV Healthcare*; Grant Recipient/ Research Support – Gilead Sciences, Merck (provided drug for NIH-sponsored clinical trial)*; Honorarium (lectures on immune activation) - Gilead Sciences, ViiV Healthcare 
  • Angela Kapalko, PA-C, AAHIVS: Advisory Board/Consultant - Gilead Sciences, ViiV Healthcare; Speaker’s Bureau - Gilead Sciences, ViiV Healthcare 
  • Colleen Kelley, MD, MPH: Grant/Research Support - Moderna, Novavax, Gilead Sciences, ViiV Healthcare, Humanigen* 
  • Ank Nijhawan, MD, MPH, MSCS: Grant/Research Support - Gilead Sciences 
  • Melanie Thompson, MD: Advisory Board/Consultant/Independent Data Monitoring Committee - Excision Biotherapeutics 
  • Puja Van Epps, MD: Grant/Research Support - ViiV Healthcare 
  • Rebecca Zash, MD: Grant/Research Support - ViiV Healthcare (donation of study product)

*indicates relationship has ended

CONFERENCE PLANNING COMMITTEE AND
SESSION CO-CHAIR DISCLOSURES

The following individuals have no relevant financial

relationships with ineligible companies to disclose:

 

  • Beatrice Aladin, MD, MPA
  • Jillian Baron, MD, MPH**
  • John Brooks, MD
  • Corette Byrd, RN, MS
  • J Kevin Carmchael, MD, FIDSA
  • Carolyn Chu, MD, MSc
  • Jonathan Colasanti, MD, MSPH
  • Carlos del Rio, MD
  • Walid El-Nahal, MD, MHS
  • Courtney V. Fletcher, PharmD
  • Rajesh Gandhi, MD
  • José I. Gutierrez, PhD, FNP-BC
  • Tomasz Z. Jodlowski, PharmD, BCPS (AQ-ID), BCIDP, AAHIVP
  • John JD Juchniewicz, MCIS, CHCP, FACEHP
  • Natalie Kirkwood RN, BSN, JD
  • Jennifer Klein, FNP-BC
  • Lorenzo McFarland, DHA, MPH, MSW**
  • Paul J. Miniter, MS
  • Edward J. Moylan, RP
  • Michelle Ogle, MD, FAAP, FPIDS, AAHIVS
  • Bruce Packett, II
  • Asa Radix, MD, PhD, MPH**
  • Dianne Rausch, PhD**
  • Jeri Sumitani, MMSc, PA-C**
  • Jessie Torgersen, MD, MHS, MSCE
  • Virginia Triant, MD, MPH
  • Ronald D. Wilcox, MD**

The following individuals have relevant financial

relationships with ineligible companies to disclose

  • Dawn Averitt, BIS: Advisory Board/Consultant - Merck, Gilead Sciences, ViiV Healthcare 
  • Meena Bansal, MD, FAASLD**: Advisory Board/Consultant - Madrigal, Novo Nordisk, Theratechnologies, Fibronostics, The Kinetix Group, GlaxoSmithKline, Pfizer, Merck, Boston Pharma, Intercept*, Myovant*; Grant/Research Support - Pfizer, Histoindex, The Kinetix Group 
  • Roger Bedimo, MD**: Advisory Board/Consultant - ViiV Healthcare, Gilead Sciences, Merck, Theratechnologies, Janssen, Shionogi; Grant/Research Support - Merck 
  • Jennifer Cocohoba, PharmD: Grant/Research Support - ViiV Healthcare, Walgreens* 
  • Eric S. Daar, MD**: Advisory Board/Consultant - Gilead Sciences Merck, ViiV Healthcare, Theratechnologies; Grant/Research Support - Gilead Sciences, ViiV Healthcare 
  • Christopher Evans, MD, MPH**: Grant/Research Support - ViiV Healthcare 
  • Oluwaseun Falade-Nwulia, MBBS, MPH**: Grant/Research Support - AbbVie 
  • Margaret Hoffman-Terry, MD,FACP, AAHIVS: Advisory Board/Consultant - Gilead Sciences, ViiV Healthcare*; Speakers Bureau - Gilead Sciences, ViiV Healthcare* 
  • H. Nina Kim, MD MSc**: Grant/Research Support - Gilead Sciences 
  • Rupa R. Patel, MD MPH: Advisory Board/Consultant - ViiV Healthcare, Gilead Sciences, Roche Diagnostics*; Grant/Research Support - Gilead Sciences, ViiV Healthcare 
  • Tonia Poteat, PhD, MPH, PA-C**: Grant/Research Support - ViiV Healthcare 
  • Renslow Sherer, MD**: Grant/Research Support - Gilead Sciences 
  • William Short MD**: Advisory Board/Consultant - ViiV Healthcare, Gilead Sciences; Grant/Research Support - Gilead Sciences, Janssen* 
  • Sarah Smith, MHS, PA-C, AAHIVS**: Advisory Board/Consultant - ViiV Healthcare, Gilead Sciences, Janssen, Merck; Speakers Bureau - ViiV Healthcare, Gilead Sciences, Janssen, Merck 
  • Babafemi Taiwo, MBBS**: Advisory Board/Consultant - GlaxoSmithKline/ViiV Healthcare, Gilead Sciences, Johnson & Johnson, Merck* 
  • Pablo Tebas, MD: Advisory Board/Consultant - ViiV Healthcare, Merck, Gilead Sciences; Grant/Research Support - Merck 
  • Melanie Thompson, MD**: Advisory Board/Consultant/Independent Data Monitoring Committee - Excision Biotherapeutics 
  • Susan Weiss, FNP-BC, MSN, AAHIVS**: Advisory Board/Consultant - ViiV Healthcare

*indicates relationship has ended
**indicates Conference or Session Cochair

Implicit Bias: Implicit bias refers to unconscious attitudes and stereotypes that influence our thoughts, judgements, decisions, and actions without our awareness. Everyone is susceptible to implicit bias, even clinicians. In healthcare, implicit biases can have a significant impact on the quality of care an individual receives. These biases can be both favorable and unfavorable, and are activated involuntarily without an individual’s awareness or intentional control. Studies have indicated that healthcare providers’ incorrect perceptions can impact providers’ communications and clinical decision-making contributing to disparities in clinical outcomes. Addressing implicit biases in healthcare is critical to improving health outcomes and promoting health equity for all patients. Patient centered care can reduce the impact of implicit bias, by treating each patient as a unique individual who may or may not hold beliefs associated with their backgrounds and circumstances. In addition, recognizing implicit bias in one’s own practice using techniques such as self-reflection and mindful clinical decision-making can ensure more equitable and effective care for all patients.


Over the past several decades, cognitive science research has demonstrated human behavior, beliefs and attitudes are shaped by automatic and unconscious cognitive processes. The healthcare profession is devoting greater attention to how these automatic and unconscious processes impact care including: (1) preferential treatment toward or against specific patient populations causing healthcare inequities, (2) influence patient-provider communications leading to misunderstandings and mistrust, and (3) impact access to healthcare and affect treatment decisions resulting in misdiagnosis, delays in treatment and specialty referrals and poor pain management. Considering one might have unconscious biases and exploring them may be uncomfortable because the very idea that they exist may conflict with how clinicians perceive themselves. It is only by becoming aware of one’s unconscious biases that members of the healthcare team can take steps to mitigate them to ensure all their patients receive quality healthcare.